1. Home
  2. DUO vs MEIP Comparison

DUO vs MEIP Comparison

Compare DUO & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DUO
  • MEIP
  • Stock Information
  • Founded
  • DUO 2011
  • MEIP 2000
  • Country
  • DUO China
  • MEIP United States
  • Employees
  • DUO N/A
  • MEIP N/A
  • Industry
  • DUO Real Estate
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • DUO Finance
  • MEIP Health Care
  • Exchange
  • DUO Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • DUO 11.4M
  • MEIP 13.3M
  • IPO Year
  • DUO 2019
  • MEIP 2003
  • Fundamental
  • Price
  • DUO $2.17
  • MEIP $6.74
  • Analyst Decision
  • DUO
  • MEIP Hold
  • Analyst Count
  • DUO 0
  • MEIP 1
  • Target Price
  • DUO N/A
  • MEIP N/A
  • AVG Volume (30 Days)
  • DUO 246.8K
  • MEIP 2.9M
  • Earning Date
  • DUO 08-29-2025
  • MEIP 09-18-2025
  • Dividend Yield
  • DUO N/A
  • MEIP N/A
  • EPS Growth
  • DUO N/A
  • MEIP N/A
  • EPS
  • DUO 7.57
  • MEIP N/A
  • Revenue
  • DUO $46,458,330.00
  • MEIP N/A
  • Revenue This Year
  • DUO N/A
  • MEIP N/A
  • Revenue Next Year
  • DUO N/A
  • MEIP N/A
  • P/E Ratio
  • DUO $0.29
  • MEIP N/A
  • Revenue Growth
  • DUO 19.00
  • MEIP 33.76
  • 52 Week Low
  • DUO $1.97
  • MEIP $1.46
  • 52 Week High
  • DUO $74.72
  • MEIP $9.00
  • Technical
  • Relative Strength Index (RSI)
  • DUO 39.97
  • MEIP 82.10
  • Support Level
  • DUO $2.06
  • MEIP $5.75
  • Resistance Level
  • DUO $2.36
  • MEIP $6.91
  • Average True Range (ATR)
  • DUO 0.15
  • MEIP 0.88
  • MACD
  • DUO 0.04
  • MEIP 0.36
  • Stochastic Oscillator
  • DUO 17.19
  • MEIP 64.69

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: